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Abstract
BACKGROUND: Gadolinium (Gd) Extracellular volume fraction (ECV) by
Cardiovascular Magnetic Resonance (CMR) has been proposed as a non-
invasive method for assessment of diffuse myocardial fibrosis. Yet only few
studies used 3 T CMR to measure ECV, and the accuracy of ECV measurements
at 3 T has not been established. Therefore the aims of the present study were
to validate measurement of ECV by MOLLI T1 mapping by 3 T CMR against
fibrosis measured by histopathology. We also evaluated the recently proposed
hypothesis that native-T1 mapping without contrast injection would be sufficient
to detect fibrosis. METHODS: 31 patients (age = 58 ± 17 years, 77% men) with
either severe aortic stenosis (n = 12) severe aortic regurgitation (n = 9) or severe
mitral regurgitation (n = 10), all free of coronary artery disease, underwent 3 T-
CMR with late gadolinium enhancement (LGE) and pre- and post-contrast MOLLI
T1 mapping and ECV computation, prior to valve surgery. LV biopsies...
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Abstract
Background: Gadolinium (Gd) Extracellular volume fraction (ECV) by Cardiovascular Magnetic Resonance (CMR)
has been proposed as a non-invasive method for assessment of diffuse myocardial fibrosis. Yet only few studies
used 3 T CMR to measure ECV, and the accuracy of ECV measurements at 3 T has not been established. Therefore
the aims of the present study were to validate measurement of ECV by MOLLI T1 mapping by 3 T CMR against
fibrosis measured by histopathology. We also evaluated the recently proposed hypothesis that native-T1 mapping
without contrast injection would be sufficient to detect fibrosis.
Methods: 31 patients (age = 58 ± 17 years, 77 % men) with either severe aortic stenosis (n = 12) severe aortic
regurgitation (n = 9) or severe mitral regurgitation (n = 10), all free of coronary artery disease, underwent 3 T-CMR
with late gadolinium enhancement (LGE) and pre- and post-contrast MOLLI T1 mapping and ECV computation,
prior to valve surgery. LV biopsies were performed at the time of surgery, a median 13 [1–30] days later, and
stained with picrosirius red. Pre-, and post-contrast T1 values, ECV, and amount of LGE were compared against
magnitude of fibrosis by histopathology by Pearson correlation coefficients.
Results: The average amount of interstitial fibrosis by picrosirius red staining in biopsy samples was 6.1 ± 4.3 %. ECV
computed from pre-post contrast MOLLI T1 time changes was 28.9 ± 5.5 %, and correlated (r = 0.78, p < 0.001)
strongly with the magnitude of histological fibrosis. By opposition, neither amount of LGE (r = 0.17, p = 0.36)
nor native pre-contrast myocardial T1 time (r = −0.18, p = 0.32) correlated with fibrosis by histopathology.
Conclusions: ECV determined by 3 T CMR T1 MOLLI images closely correlates with histologically determined
diffuse interstitial fibrosis, providing a non-invasive estimation for quantification of interstitial fibrosis in patients with
valve diseases. By opposition, neither non-contrast T1 times nor the amount of LGE were indicative of the magnitude
of diffuse interstitial fibrosis measured by histopathology.
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Background
Measurement of extracellular volume (ECV) by Gd-
DTPA Cardiovascular magnetic resonance (CMR) has
recently been proposed as a non-invasive method to
quantify myocardial interstitial volume and fibrosis [1,
2]. Several studies have compared CMR ECV estimated
by different approaches [3–7] against fibrosis by histo-
pathology, yet all these studies were performed only at
1.5 T. Presently, 3 T systems are more and more com-
monly used for cardiac MR. Yet the accuracy of meas-
urement of ECV at 3 T has not yet been evaluated.
Therefore the aims of the present study were to validate
measurement of ECV derived from MOLLI T1 map-
ping at 3 T vs histopathology. An additional aim of
our study was to examine the recently proposed hy-
pothesis that native-non contrast enhanded-T1 map-
ping would be sufficient to detect myocardial fibrosis
[8–10]. Finally we also sought to evaluate the relation
between severity of late Gd-enhancement (LGE) and
histological fibrosis.
We thus studied 31 patients scheduled to undergo aortic
or mitral valve surgery by 3 T CMR and compared ECV,
LGE and pre and post contrast T1 mapping against
measurements of myocardial fibrosis by histopathology.
Methods
Study protocol and population
Consecutive patients scheduled to undergo surgery for
either severe aortic stenosis, severe aortic or severe
mitral regurgitation at our institution (Comité éthique
hosptalo-facultaire des Cliniques Universitaires St. Luc,
Brussels, Belgium), were considered eligible for inclusion
in the study. Recruitment was performed between May
2013 and May 2014. Exclusion criteria were: history of
prior myocardial infarction; presence of significant coron-
ary artery disease on preoperative angiography; and con-
traindications to CMR (ferrometallic cerebral aneurysm
clips, pacemaker or implantable defibrillator, or severe
claustrophobia), or to injection of Gd based contest agent
(ie allergy to contrast media or renal insufficiency with
GFR-MDRD< 30 ml/min/1.73 m2). The study protocol
consisted of a Gd-enhanced MR prior to cardiac surgery
followed by myocardial biopsy at the time of surgery. The
protocol was IRB approved and patients were included
after giving written informed consent to participating in
this study. 31 participants fulfilled inclusion criteria and
consented to participating in the study (Table 1). Scan-
rescan reproducibility of pre-, post- T1 and ECV was
performed in 11 other subjects: 5 healthy volunteers
(3 males 44 ± 11 years), 4 patients with aortic stenosis
(3 males, mean age 60 ± 20 years) and 2 patients with
mitral regurgitation (2 male, mean age 65 ± 7 years).
Cardiac MR
Cardiac MR was performed using a 3 Tesla system
(Ingenia, Philips Medical Systems, Best, the Netherlands).
To assess LV myocardial function and mass, 10 to 12 con-
secutive short-axis images and 2-, 3- and 4-chamber long
axis image of the LV were acquired using a cine steady
state free precession sequence. Then, mid-ventricular
short axis Modified look locker (MOLLI) images were
acquired for T1 determination using an 11 image, 18
heart-beat 3-(3)-3-(3)-5 SSFP sequence. Imaging pa-
rameters were: Field of view: 340 mm, slice thickness
Table 1 Patients characteristics
All patients Aortic stenosis Aortic regurgitation Mitral regurgitation
(n = 31) (n = 12) (n = 9) (n = 10)
Age (year) 58 ± 17 70 ± 12 47 ± 17 54 ± 14
Male Gender (n, %) 24 (77 %) 10 (83 %) 7 (78 %) 7 (70 %)
Weight (kg) 79 ± 17 75 ± 17 88 ± 18 74 ± 12
Height (cm) 174 ± 10 171 ± 8 175 ± 10 176 ± 11
BMI (kg/m2) 26 ± 5 26 ± 5 29 ± 4 24 ± 3
Hypertension (n, %) 15 (48 %) 9 (75 %) 5 (56 %) 1 (10 %)
Smoking (n, %) 7 (23 %) 3 (25 %) 3 (33 %) 1 (10 %)
Hyperlipemia (n, %) 8 (26 %) 8 (67 %) 0 (0 %) 0 (0 %)
Diabetes Mellitus (n, %) 2 (6 %) 2 (17 %) 0 (0 %) 0 (0 %)
NYHA Class I/II 15 (48 %) / 16 (52 %) 3 (25 %) / 9 (75 %) 7 (78 %) / 2 (22 %) 5 (50 %) / 5 (50 %)
Atrial fibrillation (%) 5 (16 %) 4 (33 %) 0 (0 %) 1 (10 %)
Heart rate (bpm) 65 ± 7 65 ± 6 68 ± 8 64 ± 8
Systolic Blood Pressure (mmHg) 134 ± 18 134 ± 11 152 ± 19 119 ± 10
Diastolic Blood Pressure (mmHg) 72 ± 13 71 ± 12 71 ± 19 74 ± 9
BMI: Body Mass Index, NYHA: New York Heart Association SD: Standard Deviation
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8 mm, TR: 2.6 ms TE 1.03 ms, matrix 172 × 150 pixels
resulting in a resolution of 2x2.6 mm, Sense Factor 2,
trigger delay end-diastole, inversion times ranging from
150–3287 ms. Then, a total dose of 0.2 mmol/kg gado-
butrol (Gadovist, Schering) was injected in a 2 phase
protocol: 3 mL gadobutrol were infused as bolus
pushed by a 15 mL saline at 3 mL/s, 15 s later, the
remaining contrast dose followed by 20 mL saline were
infused at a slower rate of 1 mL/s. Ten to 15 min after
contrast injection, short- and long-axis 2D inversion re-
covery LGE images were acquired with an inversion-
recovery gradient-echo imaging sequence to evaluate
focal myocardial fibrosis, as previously described [11].
Finally, post-contrast (15 min post contrast) MOLLI T1
mapping was repeated in identical prescription as pre-
contrast T1 mapping.
For scan-rescan reproducibility, after acquisition of
the first baseline T1 mapping, the patient was removed
from the scanner and asked to stand up, then was put
back in the scanner for the acquisition of the second
set of images. A different scanner operator, starting
from new scout images, acquired images for the
second scan. After contrast administration, the same
procedure was performed for post-contrast T1 maps.
Post-contrast images were repeated without additional
contrast agent administration between both scans.
CMR data analysis
CMR images were anonymized and analyzed in double
by two experienced (CD with 6 years of CMR experi-
ence, MA with 4 year’s CMR experience level and 3
Euro-CMR certification) observers blinded to clinical
data.
Pre and post-contrast MOLLI images were processed
using the open-source software MRmap v1.4 [12] under
IDL. Images were corrected for respiratory motion when
needed, and T1 maps were generated by fitting pixels to
the equation s(t) = a – b exp (t/T1*), and T1 = T1*((b/a-1),
where a and b are constants, t is time and s(t) signal
intensity at time t. The generated pre- and post-
contrast T1 maps were stored in DICOM format and
imported into Osirix software (Pixmeo; Switzerland;
version 5.8). Pre and post contrast blood T1 times
were measured on a region of interest manually drawn
in the center of the blood pool. Pre and post myocar-
dial T1 times were measured in a segment correspond-
ing approximately to the site of the biopsy (depending
on the patient either the anterior or antero-septal
wall). To evaluate the influence of segmental hetero-
geneity on measurements we also measured T1 times,
in 6 different regions of the myocardium (anterior-, an-
terolateral, inferolateral, inferior, inferoseptal, antero-
sepal) and one global region of interest encompassing
the entire left ventricular wall. The partition coefficient
lambda (λ) and ECV were computed as:
λ ¼ 1=T1myocardium postC−1=T1myocardium preC
1=T1blood postC−1=T1blood preC
ECV=λ (1-Hematocrit). Late enhanced CMR short
axis images were analyzed using the freely available soft-
ware software Segment v1.9 (http://www.medviso.com/
products/segment) with a fully automated method [13]
validated in an animal model of experimental infarction.
The method automatically computes mean and stand-
ard deviation of signal intensity in 5 sectors per slice.
The region with the lowest mean signal intensity is con-
sidered ‘remote’ myocardium. LGE regions are consid-
ered > 2.4 SD of remote after correction for partial
volume effects. Isolated LGE regions < 1.5 ml, unless be-
ing >1 % of LV volume or being the largest LGE area in
the image volume were deducted. The pattern of LGE
was assessed by 2 independent observers (BG- 15 years
of CMR experience, and MA 4 years CMR experience,
both EuroCMR level 3 certified) who were blinded to
the clinical and histopathological data. Discordant find-
ings were resolved by consensus.
Left ventricular biopsy
In each patient, 2–4 myocardial biopsy samples weighing
approximately 25–75 mg were gathered, of which the largest
sample was analysed for histopathology, and the remaining
were preserved for other use. In patients undergoing open-
chest aortic valve replacement for aortic valve stenosis, or
aortic valve repair for aortic regurgitation, biopsies were
sampled for full width of myocardium, under direct vision
by means of a Tru-Cut® biopsy needle (CareFusion, Wauke-
gan, IL) in the anterior wall. Patients undergoing mitral valve
repair for mitral valve regurgitation by either Port-Access or
Da-Vinci minimal-access had samples taken under endo-
scopic vision taken by a surgical scissor from the anterior
septum. Samples were immediately fixed in 10 % buffered
formalin, embedded in paraffin, sectioned, and stained
with picrosirius red. Stained sections were digitalized with
a SCN400 slide scanner (Leica Biosystems, Wetzlar,
Germany). Quantification was performed using TissueIA
software (Leica Biosystems, Dublin, Ireland). After elimin-
ation of artifacts and perivascular fibrosis, area occupied
by interstitial fibrosis was expressed a percentage of total
endomyocardial area. Four different histological slices
were analyzed per patient and the average of the quantifi-
cation of the different specimens was considered the final
value of fibrosis for the patient.
Statistical methods
Statistical analyses were performed using SPSS version
20.0 software (IBM Inc, Chicago, IL). Continuous
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variables were expressed as mean ± one standard devi-
ation (SD) or medians [quartiles] if not normally distrib-
uted; categorical variables were reported as counts and
percentages. All tests were 2 sided and p value < 0.05
was considered statistically significant.
To compare baseline characteristics, T1 times and
ECV of patients with different type of valve disease,
ANOVA or Chi square tests were used. The Pearson
correlation coefficient was employed to examine the
relationship between percent LGE, pre and post con-
trast T1 times and ECV by CMR versus quantitative
interstitial fibrosis by histopathology. Intra and inter
observer and scan-rescan reproducibility of T1 times
and ECV and histopatholoy were assessed with
Bland-Altman methods and intraclass correlation
coefficient.
Results
Patient population
The characteristics of the study population are pre-
sented in Table 1. 12 patients had severe aortic sten-
osis, 10 severe mitral regurgitation, 9 severe aortic
regurgitation. Patients with aortic stenosis were signifi-
cantly older (mean age 70 ± 12 years, p = 0.002) than
patients with mitral regurgitation (54 ± 14 years) or
aortic regurgitation (47 ± 17 years). The median delay
between CMR and surgery/biopsy was 13 days [1-29]
days. Figure 1 illustrates CMR T1 mapping and histo-
pathology of a typical patient.
Myocardial fibrosis by histopathology
Myocardial biopsy was collected without complication in
all subjects. The average percentage of interstitial fibrosis
by histopathology was 6.1 ± 4.3 %, and ranged from 2.3 %
to 21.0 %. The amount of interstitial fibrosis was higher in
patients with aortic stenosis (7.3 ± 5.4 % [2.4;21.0]) than in
patients with aortic (5.2 ± 2.5 % [2.8;9.4]) and mitral regur-
gitation (5.4 ± 4.1 % [2.3;15.4]), however our study did not
have sufficient power (β = 0.8) to demonstrate statistical
significance (p = 0.46 by ANOVA) for this difference.
CMR-LGE and its relation to histology
17 patients presented small areas of LGE in non-infarct
patterns: ie focal lines (septal stripe) in 1 patient, and focal
spots or diffuse areas of LGE in midventricular or epicardial
location in 16 patients. No patient had sub-endocardial or
transmural LGE. Also no patient had LGE in the areas used
for T1 quantification. The average percentage of myocar-
dium affected by LGE measured by the automatic quantifi-
cation software was 1.1 ± 0.9 % [0.0;3.8] and did not
significantly differ (p = 0.20) between patients with aortic
stenosis (1.4 ± 0.8 %, [0.3;2.9]), aortic regurgitation (0.8 ±
0.6 % [0.24;1.77]) or mitral regurgitation (0.84 ± 1.12 %
[0.03;3.84]). There was no significant relationship between
the amount of LGE and the magnitude of diffuse fibrosis
determined by histology in either the whole group of sub-
jects (r = 0.17, p = 0.36 Fig. 2) or in patients with severe AR,
(r = 0.024, p = 0.95), severe MR (r = −0.35, p = 0.32), or se-
vere AR (r = 0.51, p = 0.091) alone.
T1 times before and after contrast and ECV and its
relation to histology
T1 times in blood and the myocardial segment corre-
sponding to the biopsy site before and after contrast and
computed ECV are shown in Table 2. Pre and post con-
trast T1 times did not differ among patients with differ-
ent pathologies. There was no significant correlation
between pre-contrast T1 time and the magnitude of
histological fibrosis in either the whole population (r =
−0.15, p = 0.41) or either of the three subgroup of patients
with different pathologies (severe AR, [r = −0.01, p = 0.99],
severe MR [r = −0.47, p = 0.17] and severe AS [r = −0.15,
p = 0.64]). Post-contrast T1 time presented a significant
but moderate inverse correlation with the amount of
histological fibrosis in the entire group of patients (r =
−0.36, p = 0.050). A significant correlation was only
present in the subgroup of patients with severe AS (r =
−0.64, p = 0.024, Fig. 3) but not in patients with severe AR
(r = −0.15, p = 0.69) or severe MR (r = −0.24, p = 0.51).
The average partition coefficient was 48.9 ± 8.6 % (range
34.4-79.6 %) and did not significantly vary among patients
with different pathologies (aortic stenosis: 48.4 ± 11.0 %,
aortic regurgitation: 47.7 ± 8.5 %, mitral regurgitation
50.7 ± 5.4 %, p = 0.73). The regional partition coefficient
Fig. 1 Example of pre and post contrast T1 maps and histophatology.
Pre and post contrast T1 Maps s and fitted T1 values (left panel) and c
corresponding histopathology (right panel)
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correlated well with the percent fibrosis by histopathology
both in the whole group of patients (r = 0.68, p < 0.001) as
well as in each of the 3 subgroup of patients with differ-
ent valve diseases: ie in severe AR, (r = 0.69, p = 0.04), in
severe MR (r = 0.58, p = 0.07) and in severe AS (r = 0.81,
p < 0.001). E*CV derived from changes of post- to pre
contrast myocardial and blood T1 times was 28.9 ± 5.5 %
(range 21.0-47 %) and did not differ among patients with
different pathologies (aortic stenosis: 30.1 ± 6.1 %, aor-
tic regurgitation: 30.1 ± 5.1 %, mitral regurgitation
29.8 ± 3.4 %, p = 0.98). ECV was found to correlate
strongly with histologically measured fibrosis both in
the whole group of patients (r = 0.78, p < 0.001, Fig. 4).
as well as in each of the 3 subgroup of patients with
different valve diseases: ie in severe AR, (r = 0.79, p =
0.011), in severe MR (r = 0.72, p = 0.020) and in severe AS
(r = 0.91, p < 0.001).
Fig. 2 Correlation between quantitatively measured LGE and fibrosis by histopathology. Correlation between quantitatively measured LGE and
% histological fibrosis for the whole population panel (a) and individual curves in patients with aortic regurgitation panel (b) mitral regurgitation panel
(c) and aortic stenosis panel (d)
Table 2 Blood and myocardial T1 times and ECV in the region
corresponding to the bioposy in different patient groups
All
patients
Aortic
stenosis
Aortic
regurgitation
Mitral
regurgitation
(n = 31) (n = 12) (n = 9) (n = 10)
T1 Blood Pre-c.
(ms)
1712 ± 99 1742 ± 131 1677 ± 59 1709 ± 79
T1 Myocardium
Pre-c. (ms)
1097 ± 70 1103 ± 87 1109 ± 63 1080 ± 56
T1 Blood Post-c.
(ms)
268 ± 47 277 ± 45 256 ± 34 268 ± 59
T1 Myocardium
Post-c. (ms)
409 ± 64 425 ± 64 405 ± 52 395 ± 75
Hct (%) 40.9 ± 3.6 40.4 ± 4.9 41.1 ± 3.6 41.4 ± 1.6
λ (%) 48.9 ± 8.6 48.4 ± 11.0 47.7±8.5 50.7 ± 5.4
ECV (%) 28.9 ± 5.5 28.8 ± 6.9 28.2 ± 5.9 29.8 ± 3.6
Pre-c.:pre-contrast, Post-c.: post-contrast, Hc: Hematrocrit, ECV: Extra Cellular
Volume, λ: partition coefficient
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Regional Varariation of myocardial T1 times, partition
coefficient and ECV and its influence on correlation with
histopathology
Segmental variation of myocardial T1 times before and
after contrast and computed partition coefficient and
ECV is shown in Table 3. Pre-contrast T1 times were
significantly lower in the anterior segment than in other
segments. However, post-contrast T1 times, computed
partition coefficient and ECG did not significantly vary
among segments. Correlations of ECV with histopatho-
logical fibrosis were similarly good when measurement
were performed in anterior (r = 0.62, p < 0.001), anterolat-
eral (r = 0.64, p < 0.001) inferoseptal (r = 0.70, P < 0.001)
and anteroseptal (r = 0.64, p < 0.001) segments, or when
ECV was computed from global T1 times of the whole LV
slice (r = 0.74, p < 0.001) Correlations with histopathology
were however poor / non existant for ECV measure-
ments performed in inferolateral (r = 0.10, p = .35) and in-
ferior (r = 0.22, p = 0.13) segments, likely because these 2
segments were more often affected by susceptibility arte-
facts on the T1 maps.
Reproducibility of measurements
Histological measurements of fibrosis had an intraobser-
ver reproducibility (ICC) of 0.99 with a bias of 0 ± 2 %
and interobserver reproducibility (ICC) of 0.82 with a
bias of 0 ± 4 %. Intra and interobserver reproducibility
for myocardial pre-contrast T1 times were ICC = 0.99
and ICC = 0.91 with bias of 7 ± 46 ms and 0 ± 55 ms re-
spectively. Intra and interobserver reproducibility for
post contrast T1 time measurement were ICC = 0.60 and
0.75 with bias of 13 ± 16 and 9 ± 29 ms respectively.
Finally, intra- and inter-observer reproducibility for ECV
were ICC = 0.51 and 0.61 with bias of −0.9 ± 2.2 % and
−0.9 ± 3.6 % respectively (Fig. 5). Scan-rescan reproduci-
bility of myocardial T1 time was ICC = 0.84 with a bias
of 2 ± 39 ms. Scan-rescan reproducibility of ECV was
ICC = 0.82 with a biais of −0.46 ± 2.4 %.
Fig. 3 Correlation between pre and post contrast myocardial T1 times and fibrosis by histopathology. Correlation between pre and post-contrast
myocardial T1 times and % histological fibrosis for the whole population panel (a) and individual curves in patients with aortic regurgitation panel
(b) mitral regurgitation panel (c) and aortic stenosis panel (d)
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Discussion
The salient findings of our study were:
1. ECV derived from 3 T CMR MOLLI T1 mapping,
15 min after bolus injection of Gd correlated well
with the magnitude of diffuse interstitial myocardial
fibrosis measured by picosirius red staining in
histopathological samples of patients undergoing
valve surgery.
2. By contrast, neither myocardial LGE extent nor
non-contrast-enhanced T1 mapping of the myocar-
dium were related to histologically measured fibrosis
content.
There is currently intense interest in the detection of
diffuse myocardial fibrosis by CMR, and several CMR
techniques have been proposed for that purpose [14].
Most approaches make use of the unique fact that Gd
Fig. 4 Correlation between ECV by Molli and fibrosis by histopathology. Correlation between ECV and % histological fibrosis for the whole population
panel (a) and individual curves in patients with aortic regurgitation panel (b) mitral regurgitation panel (c) and aortic stenosis panel (d)
Table 3 Segmental variations of pre and post contrast T1 times, partition coefficient and ECV on the mid-ventricular slice
Entire LV Anterior Anterolateral Infero-lateral Inferior Infero-septal Antero-septal P for segmental
difference (Anova)
Pre contrast T1 time (ms) 1104 ± 59 1037 ± 108* 1111 ± 73 1117 ± 80 1136 ± 84 1131 ± 89 1094 ± 95 < 0.001
Post contrast T1 time (ms) 415 ± 59 412 ± 77 410 ± 64 427 ± 69 423 ± 61 417 ± 75 409 ± 68 0.73 (NS)
Partition coefficient λ (%) 48 ± 7 48 ± 12 50 ± 11 47 ± 10 47 ± 9 50 ± 22 49 ± 9 0.51 (NS)
ECV (%) 28 ± 4 29 ± 8 29 ± 6 28 ± 6 28 ± 5 30 ± 13 29 ± 5 0.54 (NS)
Pre-c.:pre-contrast, Post-c.: post-contrast, Hc: Hematrocrit, ECV: Extra Cellular Volume, λ: partition coefficient
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based contrast agents have extravascular distribution
volume, and shorten T1 time in direct proportion to
their concentration. When myocardial tissue is replaced
by focal replacement fibrosis, or when extracellular
matrix proliferates due to diffuse interstitial fibrosis, the
distribution volume of Gd-contrast agent in the heart in-
creases. This leads to higher Gd concentration and
shorter T1 times in areas of myocardial fibrosis, relative
to normal tissue, when imaging is performed at time
when the contrast agent has equilibrated between with
blood (ie at equilibrium or several minutes after bolus
injection). Accordingly it was proposed that the magni-
tude of interstitial myocardial fibrosis can be estimated
by quantitative measurement of myocardial T1 times
Fig. 5 Bland-Altmann analysis of inter and intra observer reproducibility of T1 times and ECV. a intra observer and b inter-observer reproducibility
of post-contrastT1 times measurement, c intra- and d inter-observer reproducibility of ECV measurements. Obs: Observer, Myoc: Myocardium,
post-c.: post-contrast
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after contrast injection. Two approaches have been
proposed: One makes use from computation of Gd-
distribution volume after adjustment for contrast agent
dose, relaxivity, postcontrast delay time, heart rate, and
renal function [15]. The other approach relies on com-
putation of ECV as the ratio of change in T1 times
before and after contrast in myocardium relative to
blood, corrected for haematocrit, once an equilibrium
between plasma and myocardial contrast agent concen-
tration has been reached [3, 16, 17]. Yet so far only few
studies validated these approaches against histopath-
ology [3–7, 18] and presently, all validation studies were
performed only for 1.5 T. Also there have been only few
reports on cardiac T1 mapping [10] and quantification
of ECV at 3 T [19–23]. Indeed 3 T imaging may have
some potential limitations as opposed to 1.5 CMR. It
suffers from more pronounced inhomogeneities of both
static magnetic field (B0) and the transmit radiofre-
quency field (B1), resulting in greater inhomogeneity of
inversion and readout pulses and more pronounced off-
resonance effects. Also pre-contrast times are longer in
3 T than 1.5 T, and may not fully recover when the same
sampling schemes are used as for 1.5 T. This all might
theoretically result in differences in estimates of ECV at
3 vs 1.5 T. Our present study is the first to demonstrate
the accuracy of MOLLI T1 derived ECV at 3 T against
histopathology. It confirmed excellent correlation for
ECV measurements at 3 T against picrosirius red staining
in septal biopsy samples, thereby validating 3 T measure-
ments of ECV for estimates of diffuse intramyocardial fi-
brosis. This is in agreement with the work performed at
1.5 T [3–7, 18] and with other work [21, 22] demonstrat-
ing that field strength does not affect precision of T1 mea-
surements and ECV, and that measurement of T1 had
better scan/re-scan reproducibility at 3 T than 1.5 T.
Several recent reports suggested that T1 times before
contrast are altered by interstitial fibrosis and that native
non contrast enhanded-T1 mapping might be sufficient
to detect fibrosis [8–10]. Such native T1 imaging not re-
quiring contrast injection would have the advantage of
being faster and easier than pre- post contrast ECV
estimates. Also it would allow assessment of myocardial
fibrosis in patients with contraindications to contrast, in
particular in patients with renal failure. Therefore we also
addressed this hypothesis in our study. In opposition to
other work [10] we did not find any significant correlation
between pre-contrast T1 times and histologically mea-
sured fibrosis in our study, questioning the feasibility of
native contrast T1 imaging for the assessment of myocar-
dial fibrosis at 3 T.
Finally we also compared LGE to histological fibrosis.
Our present study employed an automated analysis
method for quantification of LGE with high reproducibil-
ity, which was validated in animals against histology [13].
Consistent with our [11] and other [24–27] prior works,
small areas of LGE in focal and patchy non-ischemic pat-
terns were present in approximately 30 % of patients with
severe valve disease. Yet, in contradiction to other studies
[26–28], we did not observe a significant correlation be-
tween the extent of LGE and histologically measured fi-
brosis in this study. This is because LGE is mainly a
measurement of focal replacement fibrosis rather than of
diffuse interstitial fibrosis, and can only reveal areas of fi-
brosis which are at least the size of an imaging voxel. Thus
the overall amount of myocardial fibrosis needs to be high
to be revealed by LGE. Since biopsies were not performed
exactly at the same level of LGE, it is also possible that the
degree of focal replacement fibrosis fluctuates throughout
the heart, and may be missed by biopsy samples from
non-LGE areas.
Clinical implications
Several studies demonstrated usefulness of ECV for
characterization of myocardial diseases, such as aortic
valve disease, cardiomyopathies, hypertrophic cardiomy-
opathies and infiltrative diseases [1, 29]. Also myocardial
post-contrast T1 times and ECV values have been asso-
ciated with greater mortality [30, 31]. This present study
confirms the accuracy of CMR estimates of ECV for
detection of diffuse interstitial myocardial fibrosis at 3 T,
suggesting that 3 T CMR can equally well be used for
clinical estimates and risk stratification of patients with
various cardiac diseases.
Study limitations
Although biopsies and MOLLI images were sampled
roughly the same region (the anterior or anteroseptal
wall) of the heart, it is impossible to assure exact spatial
correspondence between histopathology and CMR im-
aging. Also the biopsies samples are comparatively sev-
eral thousand times smaller than the regions of interest
evaluated by CMR and fibrosis in these small areas may
not necessarily be representative of overall myocardial fi-
brosis, if fibrosis is not homogenously distributed
through the heart which may be the case in diseased
hearts. It has been recognized that T1 values can vary in
different regions of the heart [32]. In our study, pre-
contrast T1 was lower in anterior region than other seg-
ments, however post-contrast T1 values and ECV did
not vary among segments. Also correlations of ECV with
histopathology were similarly good for all segments, with
the exception of inferior and inferolateral segments,
probably because of susceptibility artefacts in these re-
gions. Another limitation of our study was that only one
single slice of MOLLI images was acquired. It was re-
cently suggested that MOLLI images should be acquired
on several slices to improve the accuracy of measure-
ment. Also, to avoid overestimation of fibrosis in
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histopathological samples crossed by large blood vessels,
we excluded perivascular fibrosis although it also is a
part of extracellular volume. The picrosirius red staining
used in our study is specific for collagen. Deposition of
other extracellular proteins than collagen, for instance
amyloid, can also increase ECV. Finally, ECV measured
by CMR also includes vascular volume. Therefore
changes in capillary blood volume might also theoretically
affect the relation between ECV and interstitial fibrosis.
Also the inclusion of vascular volume and of proteins
other than collagen likely also explains why ECV is higher
than collagen content, and why the regression plot be-
tween ECV and fibrosis in Fig. 4 estimates that ECV in pa-
tients without fibrosis would be approximately 23 %. This
is however consistent with ECV values measured by other
tracers such as 14C inulin [33, 34] 14C mannitol [34], Co-
EDTA or TmDOTP5− [35]. Finally it was recently sug-
gested that ECV measurement may depend on contrast
dose, since ECV measured in healthy volunteers using
high contrast doses (0.2 mmol/kg gadovist, as used in this
work) were lower than for lower doses [31]. Whether this
may have influenced the accuracy of our results remains
however unknown.
Conclusions
Our results indicate that ECV determined by 3 T CMR
T1 MOLLI images closely correlates with histologically
determined diffuse interstitial fibrosis, demonstrating the
accuracy of this method for non-invasive quantification
of interstitial fibrosis in patients with myocardial dis-
eases. By opposition, non-contrast T1 mapping and LGE
were not found to represent reliable measurements of
interstitial fibrosis in patients with valve disease at 3 T.
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